|
|
|
| Clinical effect of Professor Lin Jiakun’s “ways to decrease yang qi” in the treatment of chronic obstructive pulmonary disease with syndrome of phlegm-heat obstructing lung |
| ZHAO Yi1 HAN Shiwei2▲ LIN Jiakun1 |
1.Emergency Department, Pingxiang Hospital of Traditional Chinese Medicine, Jiangxi Province, Pingxiang 337000, China;
2.College of Basic Medicine, Changchun University of Chinese Medicine, Jilin Province, Changchun 130117, China |
|
|
|
Abstract Objective To explore the clinical efficacy of Professor Lin Jiakun’s “ways to decrease yang qi” in the treatment of chronic obstructive pulmonary disease with syndrome of phlegm-heat obstructing lung. Methods A total of 72 cases of chronic obstructive pulmonary disease patients with syndrome of phlegm-heat obstructing lung admitted to Respiratory Department, ICU, and Emergency Department of Pingxiang Hospital of Traditional Chinese Medicine (TCM)from January 2019 to July 2020 were selected and randomly divided into study group and control group by random number table method, with 36 cases in each group. The control group was routinely treated with antispasmodic, antiasthmatic, anti-inflammatory, and phlegm-resolving drugs. The study group was added with “ways to decrease yang qi” Chinese medicine prescription on the basis of control group. The related indexes of lung function, 36-item short form health survey (SF-36), clinical efficacy, TCM syndrome scores, and adverse reactions were compared between the two groups. Results After treatment, the arterial blood oxygen partial pressure (PO2), forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) in the two groups were significantly higher than those before treatment, carbon dioxide partial pressure (PCO2) was significantly lower than that before treatment; after treatment, the PO2, FEV1, FVC in the treatment group were significantly higher than those in the control group, and PCO2 was significantly lower than that in the control group (P ＜ 0.05). After treatment, the SF-36 scores of the two groups were significantly higher than those before treatment, which of the treatment group was higher than that of control group (P ＜ 0.05). The total effective rate of treatment group was higher than that in the control group, the difference was statistically significant (P ＜ 0.05). After treatment, the TCM syndrome scores in the two groups were lower than those before treatment, which of the treatment group was higher than that of the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion The application of “ways to decrease yang qi” in the treatment of chronic obstructive pulmonary disease with syndrome of phlegm-heat obstructing lung has significant clinical effect, without increasing the incidence of adverse reactions, which can significantly improve the quality of life and clinical symptoms, and it is worthy of promotion.
|
|
|
|
|
|
[1] 陈亚红.2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J].中国医学前沿杂志，2019，11（1）：1-15.
[2] Wang C，Xu J，Yang L，et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China（the China Pulmonary Health[CPH]study）：a national cross-sectional study [J]. Lancet，2018，391（10131）：1706-1717.
[3] 付永铎.中西医结合治疗慢性阻塞性肺疾病急性加重期临床观察[J].山西中医，2019，35（1）：26-27，30.
[4] 张骏濠.现代名老中医治疗慢性阻塞性肺疾病用药规律研究及临床验案举隅[D].广州：广州中医药大学，2017.
[5] 洪新，雷文慧，崔社怀，等.慢性阻塞性肺疾病与支气管哮喘患者的气道可逆性分析[J].中华肺部疾病杂志：电子版，2014，7（1）：64-65.
[6] 战玉芳，徐凌忠.慢性阻塞性肺疾病肺康复治疗策略与评价指标研究进展[J].齐鲁护理杂志，2016，22（5）：51-53.
[7] 中华医学会，中华医学会杂志社，中华医学会全科医学分会，等.慢性阻塞性肺疾病基层诊疗指南（2018年）[J].中华全科医师杂志，2018，17（11）：856-870.
[8] 陈仕锋，黄敏於，彭显如，等.肺音可以作为首诊慢性阻塞性肺疾病严重程度的判断指标[J].南方医科大学学报，2020，40（2）：177-182.
[9] 中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医诊疗指南（2011版）[J].中医杂志，2012，53（1）：80-84.
[10] 安晓洁，乜庆荣，邓赶飞.慢性阻塞性肺疾病稳定期患者疾病严重程度与生命质量的相关性研究[J].中国社会医学杂志，2013，30（5）：339-341.
[11] 中华中医药学会内科分会肺系病专业委员会.慢性阻塞性肺疾病中医诊疗指南（2011版）[J].中医杂志，2012， 53（1）：80-84.
[12] 王蔚文.临床疾病诊断与疗效判断标准[M].北京：科学技术文献出版社，2010.
[13] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002：56.
[14] 彭景钦，叶伟煊；范发才.金水六君煎对重度、极重度慢性阻塞性肺疾病患者临床症状及炎症反应的影响[J].中国老年学杂志，2020，40（13）：2759-2762.
[15] 陶玙婧，杨云柯.慢性阻塞性肺疾病中西医临床研究进展[J].陕西中医，2014，35（7）：934-936.
[16] 周仲英.中医内科学[M].北京：中国中医药出版社，2003：117-123.
[17] 吴孝政，王振兴，王飞.基于多元统计方法的慢性阻塞性肺疾病稳定期中医证候分布规律及辨证要素的探讨[J].时珍国医国药，2018，29（6）：1493-1497.
[18] 刘洪，张弛，陈云风.清热解毒法对慢性阻塞性肺疾病气道炎症与细胞因子水平的影响[J].中华实用中西医杂志，2003，3（16）：1740-1741.
[19] 李治军，刘明，易小玲，等.西药联合芪黄益肺合剂治疗慢性阻塞性肺疾病急性加重期肺肾气虚证临床观察[J].中国民族民间医药，2019，28（20）：99-101.
[20] 郭光辉，郑岚，杨宏志，等.化痰降气活血汤联合常规西药治疗哮喘-慢性阻塞性肺疾病重叠的临床效果[J].中国医药导报，2019，16（26）：137-140，144.
[21] 彭磊，夏卫明，何健忠，等.温阳化痰汤对慢性阻塞性肺疾病急性加重合并肺源性心脏病（痰湿阳虚证）的临床研究[J].中国中医急症，2019，28（8）：1423-1426.
[22] 何振雄，朱美群，李世闻.“三小汤”治疗慢性阻塞性肺疾病的疗效探析[J].内蒙古中医药，2017，36（3）：38-39.
[23] 安会明，苗丹丹，吕蓓蓓，等.加味补中益气汤辅助治疗慢性阻塞性肺疾病伴呼吸衰竭的临床[J].中国医药导报，2020，17（17）：153-157.
[24] 吕小亮，沈英森，赵长鹰，等.金水六君煎胶囊对慢支大鼠肺表面活性物质影响的实验研究[J].广州医药，2001，32（6）：6-8.
[25] 林家坤.张仲景治阳三十六法钩玄之二[J].实用中西医结合临床，2018，18（7）：125-126.
[26] 林家坤.张仲景治阳三十六法钩玄[M].北京：中医古籍出版社，2018：45-46. |
|
|
|
